Nitazoxanide
Nitazoxanide is a pharmaceutical drug with 76 clinical trials. Currently 7 active trials ongoing. Historical success rate of 82.7%.
Success Metrics
Based on 43 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
35
Mid Stage
29
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
75.4%
43 of 57 finished
24.6%
14 ended early
7
trials recruiting
76
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Nitazoxanide for Treatment of Cryptosporidium in Children
AGILE (Early Phase Platform Trial for COVID-19)
Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children
Nitazoxanide in Patients With Ulcerative Colitis
Clinical Trials (76)
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
Nitazoxanide for Treatment of Cryptosporidium in Children
AGILE (Early Phase Platform Trial for COVID-19)
Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children
Nitazoxanide in Patients With Ulcerative Colitis
NNITS-Nitazoxanide for Norovirus in Transplant Patients Study
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children
Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
Treatment of Cryptosporidiosis
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Nitazoxanide in Patients With Metastatic Colorectal Cancer
Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers
Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 76